CTOs on the Move

Silicycle

www.silicycle.com

 
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.silicycle.com
  • 2500 boul du Parc-Technologique
    Quí©bec, QC CAN G1P 4S6
  • Phone: 418.874.0054

Executives

Name Title Contact Details

Similar Companies

BestSelf

A change for the Best is here! Child & Adolescent Treatment Services and Lake Shore Behavioral Health are proud to become BestSelf Behavioral Health!

Signature Pharmacy

Signature Pharmacy is a Winter Park, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medaus Pharmacy

Medaus Pharmacy is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines. The Company`s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013. ThromboGenics signed a strategic partnership with Alcon, a division of Novartis, for the commercialization of JETREA® outside the United States. ThromboGenics is headquartered in Leuven, Belgium, and has offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR.

Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company developing novel drugs, leveraging technology from the lab of Nobel laureate Dr. Paul Greengard, for the treatment of neuropsychiatric and neurodegenerative diseases. The Company is developing its lead drug candidate, lumateperone, a first-in-class molecule, which is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer`s disease. The Company is also utilizing its phosphodiesterase (PDE) platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders. The lead compound in the PDE platform, ITI-214, a PDE1 inhibitor is being developed for the treatment of CNS and non-CNS indications.